• NervAlign® Nerve Cuff receives registration approval from India's CDSCO.
• First product approval in the significant and growing Indian market.
• Clears the way for commercial rollout across India.

ReNerve Limited, an Australian biotechnology company, has received marketing approval for its NervAlign® Nerve Cuff in India from the Central Drugs Standard Control Organization (CDSCO). This approval is a major milestone for the company as it enters the Indian market, which is one of the largest and fastest-growing healthcare markets globally. The approval allows ReNerve and its Indian commercialization partner, NetCentrix Ventures, to begin the commercial rollout of the NervAlign® Nerve Cuff across India. The Indian nerve repair and regeneration market is valued at approximately USD $700 million, driven by a significant population and high rates of trauma-related peripheral nerve injuries.